Cover Page |
12 Months Ended |
|---|---|
|
Dec. 31, 2025
shares
| |
| Document Information [Line Items] | |
| Document Type | 20-F |
| Amendment Flag | false |
| Document Period End Date | Dec. 31, 2025 |
| Document Fiscal Year Focus | 2025 |
| Document Fiscal Period Focus | FY |
| Trading Symbol | ASND |
| Entity Registrant Name | Ascendis Pharma A/S |
| Entity Central Index Key | 0001612042 |
| Current Fiscal Year End Date | --12-31 |
| Entity Well-known Seasoned Issuer | Yes |
| Entity Current Reporting Status | Yes |
| Entity Filer Category | Large Accelerated Filer |
| Entity Emerging Growth Company | false |
| Entity Shell Company | false |
| Entity Common Stock, Shares Outstanding | 61,977,408 |
| Entity Voluntary Filers | No |
| Entity Interactive Data Current | Yes |
| Document Accounting Standard | International Financial Reporting Standards |
| Entity Incorporation, State or Country Code | G7 |
| Entity Address, Country | DK |
| Entity Address, Postal Zip Code | DK-2900 |
| Document Annual Report | true |
| Document Transition Report | false |
| Document Shell Company Report | false |
| Document Registration Statement | false |
| Title of 12(b) Security | Ordinary shares |
| Security Exchange Name | NASDAQ |
| Entity Address, Address Line One | Tuborg Boulevard 12 |
| Entity Address, City or Town | Hellerup |
| Entity File Number | 001-36815 |
| ICFR Auditor Attestation Flag | true |
| Document Financial Statement Error Correction | false |
| Auditor Name | Deloitte Statsautoriseret Revisionspartnerselskab |
| Auditor Firm ID | 1294 |
| Auditor Location | Copenhagen, Denmark |
| Auditor Opinion | Opinions on the Financial Statements and Internal Control over Financial Reporting We have audited the accompanying consolidated statements of financial position of Ascendis Pharma A/S and subsidiaries (the “Company”) as of December 31, 2025 and 2024, the related consolidated statements of profit or (loss) and other comprehensive income or (loss), the consolidated statements of changes in equity, and the consolidated statements of cash flows for each of the three years in the period ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). We also have audited the Company’s internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with IFRS Accounting Standards as issued by the International Accounting Standards Board and as adopted by the European Union. Also, in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO. |
| Business Contact [member] | |
| Document Information [Line Items] | |
| Entity Address, Country | DK |
| Entity Address, Postal Zip Code | DK-2900 |
| Entity Address, Address Line One | Tuborg Boulevard 12 |
| Entity Address, City or Town | Hellerup |
| Contact Personnel Name | Jan Møller Mikkelsen |
| City Area Code | +45 |
| Local Phone Number | 70 22 22 44 |
| American Depositary Shares [member] | |
| Document Information [Line Items] | |
| Title of 12(b) Security | American Depositary Shares |
| Security Exchange Name | NASDAQ |
| No Trading Symbol Flag | true |